These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16544982)

  • 1. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.
    Singh NP; Miller RW; Yolcu ES; Kilinc MO; Oechsli M; Huseby R; Taylor DD; Perry MT; Larocca RV; Shirwan H
    Hum Gene Ther; 2006 Mar; 17(3):334-46. PubMed ID: 16544982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
    Singh NP; Yolcu ES; Taylor DD; Gercel-Taylor C; Metzinger DS; Dreisbach SK; Shirwan H
    Cancer Res; 2003 Jul; 63(14):4067-73. PubMed ID: 12874008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
    Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
    J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
    Zeng W; Su M; Anderson KS; Sasada T
    Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
    Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
    Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.
    Foster AE; Leen AM; Lee T; Okamura T; Lu A; Vera J; Atkinson R; Bollard CM; Dotti G; Rooney CM
    J Immunother; 2007; 30(5):506-16. PubMed ID: 17589291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.
    Dols A; Smith JW; Meijer SL; Fox BA; Hu HM; Walker E; Rosenheim S; Moudgil T; Doran T; Wood W; Seligman M; Alvord WG; Schoof D; Urba WJ
    Hum Gene Ther; 2003 Jul; 14(11):1117-23. PubMed ID: 12885350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.
    Singh NP; Yolcu ES; Askenasy N; Shirwan H
    Ann N Y Acad Sci; 2005 Nov; 1056():344-58. PubMed ID: 16387700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma.
    Gückel B; Meyer GC; Rudy W; Batrla R; Meuer SC; Bastert G; Wallwiener D; Moebius U
    Cancer Gene Ther; 1999; 6(3):228-37. PubMed ID: 10359208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
    Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
    Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells.
    Mackensen A; Wittnebel S; Veelken H; Noppen C; Spagnoli GC; Lindermann A
    Eur Cytokine Netw; 1999 Sep; 10(3):329-36. PubMed ID: 10477389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro.
    Kaufmann AM; Gissmann L; Street D; Schreckenberger C; Hunter M; Qiao L
    Cell Immunol; 1996 May; 169(2):246-51. PubMed ID: 8620552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral transduction of primary myeloma cells with CD80 and CD154 generates antimyeloma effector T cells.
    Cignetti A; Vallario A; Follenzi A; Circosta P; Capaldi A; Gottardi D; Naldini L; Caligaris-Cappio F
    Hum Gene Ther; 2005 Apr; 16(4):445-56. PubMed ID: 15871676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
    Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
    Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.